Xarelto Lawsuit Plaintiffs Cite Multiple Studies Which Link Drug To Excessive Bleeding Concerns

January 29, 2016 – – BloodThinnerHelp.com reports on multiple studies which help to support plaintiff arguments in recent Xarelto lawsuits. The results of these studies appear to highlight unsettling links between blood-thinning drug Xarelto and an increased risk for spontaneous and uncontrollable bleeding episodes in those taking it.

Xarelto gained FDA approval in 2011, and was later released to the market as a new-generation anticoagulant. The drug was originally approved to treat patients who had recently undergone knee or hip replacement surgeries to prevent the development of blood clots. This approved use was later expanded to include treatment for patients with atrial fibrillation heart conditions, pulmonary embolism, or deep vein thrombosis, as a preventative measure for strokes and blood clots.

Things quickly changed in the public’s eye, however, as reports of serious adverse health events linked to Xarelto began to surface. Across the U.S., the drug was allegedly connected to the development of blood clots, as well as strokes, pulmonary embolisms, internal and external spontaneous uncontrollable bleeding episodes, and other serious health problems.

Doctors Judy H. Hun and John C. Hwang stepped up to conduct some studies on the drug through their practice, as they had commonly prescribed it to patients and began to get concerned. The doctors indicated that three of their patients had developed “spontaneous vitreous hemorrhage” (or eye bleeding) while taking Xarelto, and so they began to investigate things further. Their study results indicated that the risk of sudden eye bleeds was elevated for patients who had switched from taking a traditional blood thinner to taking Xarelto.

Their second study was conducted between October 1st 2010 and March 31st, 2012. This one evaluated the results of patients from across the nation who were using Xarelto, Pradaxa, and Warfarin (all various brands and types of blood thinners). For this study, doctors collected data from a sample of 46,000 patients: 39,607 warfarin users, 4,907 Pradaxa users, and 1,649 Xarelto users. Research conducted on these patients indicated “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

Xarelto lawsuit cases now number over 2,800 in federal court. They have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592, and are being overseen by the Honorable Judge Eldon Fallon in New Orleans, Louisiana. As they await trial, these case numbers are only expected to increase, and they are joined by another 550 cases consolidated to form a mass tort group in Philadelphia, Pennsylvania. Plaintiffs involved in all lawsuits have linked the drug to serious and even fatal bleeding events.

Attorney Joseph Osborne is hoping to assist anyone who used Xarelto and later suffered from health complications. He believes that these individuals may be entitled to legal action and significant compensation, and that everyone deserves the opportunity to fully explore their legal rights and pursue justice. At this time, he is offering complimentary legal consultations to affected individuals.

To obtain the latest information concerning Xarelto lawsuits or ask questions, please call Attorney Osborne at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60007791